ABIOLA OLADAPO, PhD

Sobi Inc

Poster(s):

• (220) Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database
  Wednesday, October 29, 2025

• (221) Transfusion-related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Pacritinib Compared to Best Available Therapy Based on PERSIST-2 Trial
  Wednesday, October 29, 2025

• (237) Patient, Caregiver, and Physician Perspectives on the Burden of Disease in Uncontrolled Gout and its Treatment: Concept Elicitation
  Wednesday, October 29, 2025

• (289) Economic burden of macrophage activation syndrome (MAS) in patients with Still’s disease (systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD)): analysis of a US national administrative claims database
  Wednesday, October 29, 2025

• (359) Healthcare Resource Utilization in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Study Results
  Wednesday, October 29, 2025